English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 30 July 2013, 07:55 HKT/SGT
Share:
    

Source: INC Research, LLC
INC Research Strengthens Asia/Pacific Capabilities Through Two New Offices in Japan
Offices in Osaka and Shinagawa in Tokyo provide strong clinical development hub for customers in world's second largest pharmaceutical market

Raleigh, NC, July 30, 2013 - (ACN Newswire) - INC Research LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process(R) for delivering reliable results, today announced the establishment of INC Research Japan KK with the opening of new locations in Osaka and the Shinagawa ward in Tokyo. The new operations provide INC Research's global drug development customers access to an increasingly significant market and further expand the Company's presence in the Asia/Pacific region. INC Research now has 20 offices in key locations across the Asia/Pacific region in addition to Japan, including a presence in China, India, Australia, Singapore, Philippines, South Korea, Taiwan, Hong Kong, Malaysia, Thailand, Indonesia and New Zealand.

"There is a growing enthusiasm from both pharma and government sectors for Japan to be involved in both global and regional clinical trials," said Garth Tierney , Executive Vice President, Asia/Pacific. "In response, INC Research is implementing a very considered approach to the market that will create greater confidence among our customers in conducting trials in Japan, as well as ultimately provide more direct influence on how trials are conducted. Our Japanese customers already have responded positively to our Trusted Process methodology as it fits well with their requirements for high quality and predictability. We are very enthusiastic about bringing the continued benefits of drug development in this country to our customers."

Through INC Research's unique approach to the Japan market, the two offices initially will feature a core group of highly qualified, English-speaking management, regulatory and therapeutic staff who will create a bridge between the Company's Trusted Process methodology and the way clinical research has traditionally been conducted in Japan. The establishment of Japanese business operations builds on INC Research's long-term experience in Japan where it has partnered with local CROs to conduct numerous trials across a variety of therapeutic areas.

The Osaka office is located at Level 19 Hilton Plaza West Office Tower, 2-2-2 UMEDA, Kita-ku, Osaka 530-0001 and the Tokyo office is located at Level 28 Shinagawa Intercity Tower A, 2-15-1 Konan Minato-ku, Tokyo 108-6028. Both locations are strategically placed to serve major drug development areas and are connected by the region's bullet train.

INC Research has provided Phase I to IV clinical development services in the Asia/Pacific region for nearly 20 years , conducting more than a 1,000 studies across a broad range of therapeutic areas. For more information on INC Research's clinical trial services and experience in Japan, please call +81-6-6450-9360 or visit the website.

About INC Research

INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process(R) methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.

Contact:
Lori Dorer, Media +1-513-345-1685


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: INC RESEARCH, LLC via Thomson Reuters ONE

Topic: Establishment of New Branch
Source: INC Research, LLC


https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

INC Research, LLC Related News
Nov 7, 2014 08:50 HKT/SGT
INC Research Announces Pricing of Initial Public Offering
Oct 7, 2014 07:10 HKT/SGT
INC Research Files Registration Statement for Initial Public Offering
Oct 3, 2014 10:30 HKT/SGT
INC Research Demonstrates Continued Dedication to Site Relationships at 2014 SCRS Site Solutions Summit
Oct 2, 2014 07:20 HKT/SGT
INC Research Further Reinforces Commitment to Clinical Research Sites and Patients through Creation of New Leadership Role
Aug 6, 2014 03:30 HKT/SGT
INC Research's Tara Fitzgerald and Judy Swilley Named to Annual PharmaVOICE 100
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575